Clinically meaningful change in itch intensity scores: An evaluation in patients with chronic kidney disease-associated pruritus

J Am Acad Dermatol. 2021 Apr;84(4):1132-1134. doi: 10.1016/j.jaad.2020.06.991. Epub 2020 Jun 27.

Authors

Margaret Vernon¹, Sonja Ständer², Catherine Munera³, Robert H Spencer³, Frédérique Menzaghi⁴

Affiliations

¹ Evidera, Bethesda, Maryland.
² Center for Chronic Pruritus, Department of Dermatology, University Hospital Münster, Münster, Germany.
³ Cara Therapeutics, Stamford, Connecticut.
⁴ Cara Therapeutics, Stamford, Connecticut. Electronic address: [email protected].

PMID: 32603719
DOI: 10.1016/j.jaad.2020.06.991

No abstract available

Publication types

Clinical Trial, Phase II
Multicenter Study
Randomized Controlled Trial

MeSH terms

Adult
Aged
Aged, 80 and over
Antipruritics / therapeutic use*
Double-Blind Method
Female
Humans
Male
Middle Aged
Piperidines / therapeutic use*
Pruritus / drug therapy*
Pruritus / etiology*
Quality of Life
Renal Dialysis
Renal Insufficiency, Chronic / complications*
Renal Insufficiency, Chronic / therapy
Treatment Outcome

Substances

Antipruritics
Piperidines
difelikefalin